Dendritic cell-based immunotherapy for rheumatoid arthritis: From bench to bedside

Immune Network

Volumn 16, Issue 1, 2016, Pages 44-51

  Ahmed, Md Selim ^a,b   Bae, Yong Soo ^a  

^a Sungkyunkwan University   (South Korea)

^b PATUAKHALI SCIENCE AND TECHNOLOGY UNIVERSITY   (Bangladesh)

Author keywords

Clinical study; Future; Immunotherapy; Limitation; Mouse collagen induced arthritis (CIA); Rheumatoid arthritis (RA); Tolerance; Tolerogenic dendritic cell (tolDC); Treg

Indexed keywords

AUTOIMMUNITY; CELL MATURATION; CELL THERAPY; CLINICAL TRIAL (TOPIC); COLLAGEN-INDUCED ARTHRITIS; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 85013754569     PISSN: 15982629     EISSN: 20926685     Source Type: Journal    
DOI: 10.4110/in.2016.16.1.44     Document Type: Review

References (69)

1. Hilkens, C. M., and J. D. Isaacs. 2013. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin. Exp. Immunol. 172: 148-157.
2. Choy, E. H., A. F. Kavanaugh, and S. A. Jones. 2013. The problem of choice: current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 9: 154-163.
3. Singh, J. A., R. Christensen, G. A. Wells, M. E. Suarez-Almazor, R. Buchbinder, M. A. Lopez-Olivo, G. E. Tanjong, and P. Tugwell. 2009. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. CD007848.
4. Stoop, J. N., J. H. Robinson, and C. M. Hilkens. 2011. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann. Rheum. Dis. 70: 1526-1533.
5. Steinman, R. M. 2012. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30: 1-22.
6. Steinman, R. M., and M. C. Nussenzweig. 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. U. S. A. 99: 351-358.
7. Jonuleit, H., E. Schmitt, K. Steinbrink, and A. H. Enk. 2001. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22: 394-400.
8. + regulatory T cells including suppressors of alloreactivity. Immunol. Rev. 212: 314-329.
9. Roncarolo, M. G., M. K. Levings, and C. Traversari. 2001. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193: F5-F9.
10. Voigtlander, C., S. Rossner, E. Cierpka, G. Theiner, C. Wiethe, M. Menges, G. Schuler, and M. B. Lutz. 2006. Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J. Immunother. 29: 407-415.
11. Kleindienst, P., C. Wiethe, M. B. Lutz, and T. Brocker. 2005. Simultaneous induction of CD4 T cell tolerance and CD8 T cell immunity by semimature dendritic cells. J. Immunol. 174: 3941-3947.
12. Rutella, S., S. Danese, and G. Leone. 2006. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108: 1435-1440.
13. Harden, J. L., and N. K. Egilmez. 2012. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol. Invest 41: 738-764.
14. Quaratino, S., L. P. Duddy, and M. Londei. 2000. Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 97: 10911-10916.
15. Lutz, M. B. 2012. Therapeutic potential of semi-mature dendritic cells for tolerance induction. Front. Immunol. 3: 123.
16. Bianco, N. R., S. H. Kim, M. A. Ruffner, and P. D. Robbins. 2009. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum. 60: 380-389.
17. Kim, S. H., S. Kim, T. J. Oligino, and P. D. Robbins. 2002. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol. Ther. 6: 584-590.
18. Yang, J., S. M. Bernier, T. E. Ichim, M. Li, X. Xia, D. Zhou, X. Huang, G. H. Strejan, D. J. White, R. Zhong, and W. P. Min. 2003. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J. Leukoc. Biol. 74: 438-447.
19. Menges, M., S. Rossner, C. Voigtlander, H. Schindler, N. A. Kukutsch, C. Bogdan, K. Erb, G. Schuler, and M. B. Lutz. 2002. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 195: 15-21.
20. Lim, D. S., M. S. Kang, J. A. Jeong, and Y. S. Bae. 2009. Semimature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur. J. Immunol. 39: 1334-1343.
21. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101: 455-458.
22. Bach, J. F. 2003. Regulatory T cells under scrutiny. Nat. Rev. Immunol. 3: 189-198.
23. + regulatory T cells. Nat. Immunol. 4: 330-336.
24. + T regulatory cells. Nat. Immunol. 4: 337-342.
25. Buckner, J. H. 2010. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10: 849-859.
26. Thomson, A. W. and P. D. Robbins. 2008. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann. Rheum. Dis. 67 Suppl 3: iii90-iii96.
27. Zheng, J., H. Y. Jiang, J. Li, H. C. Tang, X. M. Zhang, X. R. Wang, J. T. Du, H. B. Li, and G. Xu. 2012. MicroRNA-23b promotes tolerogenic properties of dendritic cells in vitro through inhibiting Notch1/NF-kappaB signalling pathways. Allergy 67: 362-370.
28. Stumpfova, Z., R. Hezova, A. C. Meli, O. Slaby, and J. Michalek. 2014. MicroRNA profiling of activated and tolerogenic human dendritic cells. Mediators Inflamm. 2014: 259689.
29. Valencia, J., C. Hernandez-Lopez, V. G. Martinez, L. Hidalgo, A. G. Zapata, A. Vicente, A. Varas, and R. Sacedon. 2011. Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. J. Immunol. 187: 4129-4139.
30. Zhu, B., T. Buttrick, R. Bassil, C. Zhu, M. Olah, C. Wu, S. Xiao, W. Orent, W. Elyaman, and S. J. Khoury. 2013. IL-4 and retinoic acid synergistically induce regulatory dendritic cells expressing Aldh1a2. J. Immunol. 191: 3139-3151.
31. Steinbrink, K., M. Wolfl, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159: 4772-4780.
32. Yarilin, D., R. Duan, Y. M. Huang, and B. G. Xiao. 2002. Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis. Clin. Exp. Immunol. 127: 214-219.
33. Boks, M. A., J. R. Kager-Groenland, M. S. Haasjes, J. J. Zwaginga, S. M. van Ham, and B. A. ten. 2012. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction--a comparative study of human clinical-applicable DC. Clin. Immunol. 142: 332-342.
34. + T regulatory cells and promote organ transplant tolerance. J. Immunol. 178: 7018-7031.
35. Pothoven, K. L., T. Kheradmand, Q. Yang, J. L. Houlihan, H. Zhang, M. Degutes, S. D. Miller, and X. Luo. 2010. Rapamycinconditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-beta1 for islet transplantation. Am. J. Transplant. 10: 1774-1784.
36. Salazar, L., O. Aravena, P. Abello, A. Escobar, J. Contreras-Levicoy, N. Rojas-Colonelli, D. Catalan, A. Aguirre, R. Zuniga, B. Pesce, C. Gonzalez, R. Cepeda, M. Cuchacovich, M. C. Molina, F. Salazar-Onfray, M. Delgado, R. E. Toes, and J. C. Aguillon. 2008. Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. Ann. Rheum. Dis. 67: 1235-1241.
37. van der, K. D., E. Latz, J. F. Brouwers, Y. C. Kruize, M. Schmitz, E. A. Kurt-Jones, T. Espevik, E. C. de Jong, M. L. Kapsenberg, D. T. Golenbock, A. G. Tielens, and M. Yazdanbakhsh. 2002. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J. Biol. Chem. 277: 48122-48129.
38. Maldonado, R. A., and U. H. von Andrian. 2010. How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108: 111-165.
39. Roncarolo, M. G., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212: 28-50.
40. Papatriantafyllou, M. 2011. Tolerance: both natural and induced TReg talents needed. Nat. Rev. Immunol. 11: 500.
41. Qureshi, O. S., Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, T. Z. Hou, C. E. Futter, G. Anderson, L. S. Walker, and D. M. Sansom. 2011. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600-603.
42. Gregori, S., K. S. Goudy, and M. G. Roncarolo. 2012. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front. Immunol. 3: 30.
43. Mellor, A. L., B. Baban, P. Chandler, B. Marshall, K. Jhaver, A. Hansen, P. A. Koni, M. Iwashima, and D. H. Munn. 2003. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171: 1652-1655.
44. + regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 204: 1757-1764.
45. Sun, C. M., J. A. Hall, R. B. Blank, N. Bouladoux, M. Oukka, J. R. Mora, and Y. Belkaid. 2007. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204: 1775-1785.
46. + dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1. Exp. Hematol. 43: 268-276.
47. + dendritic cells. Gastroenterology 141: 1813-1820.
48. Goubier, A., B. Dubois, H. Gheit, G. Joubert, F. Villard-Truc, C. sselin-Paturel, G. Trinchieri, and D. Kaiserlian. 2008. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 29: 464-475.
49. + T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J. Immunol. 172: 1991-1995.
50. Harry, R. A., A. E. Anderson, J. D. Isaacs, and C. M. Hilkens. 2010. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis. 69: 2042-2050.
51. Sato, K., N. Yamashita, N. Yamashita, M. Baba, and T. Matsuyama. 2003. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18: 367-379.
52. + regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J. Immunol. 174: 7006-7013.
53. Ferreira, G. B., C. A. Gysemans, J. Demengeot, J. P. da Cunha, A. S. Vanherwegen, L. Overbergh, T. L. Van Belle, F. Pauwels, A. Verstuyf, H. Korf, and C. Mathieu. 2014. 1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J. Immunol. 192: 4210-4220.
54. Adorini, L. 2003. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. N. Y. Acad. Sci. 987: 258-261.
55. Diana, J., Y. Simoni, L. Furio, L. Beaudoin, B. Agerberth, F. Barrat, and A. Lehuen. 2013. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19: 65-73.
56. Li, Q., B. Xu, S. A. Michie, K. H. Rubins, R. D. Schreriber, and H. O. McDevitt. 2008. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 105: 12439-12444.
57. Park, J. E., J. Jang, J. H. Choi, M. S. Kang, Y. J. Woo, Y. R. Seong, C. B. Choi, H. S. Lee, S. C. Bae, and Y. S. Bae. 2015. DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice. J. Immunol. Res. 2015: 834085.
58. Zhang, L., J. Fu, K. Sheng, Y. Li, S. Song, P. Li, S. Song, Q. Wang, J. Chen, J. Yu, and W. Wei. 2015. Bone marrow CD11b(+)F4/80(+) dendritic cells ameliorate collagen-induced arthritis through modulating the balance between Treg and Th17. Int. Immunopharmacol. 25: 96-105.
59. Ren, Y., Y. Yang, J. Yang, R. Xie, and H. Fan. 2014. Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice. Int. Immunopharmacol. 21: 247-254.
60. Li, X., Y. Han, Q. Zhou, H. Jie, Y. He, J. Han, J. He, Y. Jiang, and E. Sun. 2016. Apigenin, a potent suppressor of dendritic cell maturation and migration, protects against collagen-induced arthritis. J. Cell. Mol. Med. 20: 170-180.
61. Yang, J., Y. Yang, Y. Ren, R. Xie, H. Zou, and H. Fan. 2013. A mouse model of adoptive immunotherapeutic targeting of autoimmune arthritis using allo-tolerogenic dendritic cells. PLoS One 8: e77729.
62. Thomas, R., S. Street, N. Ramnoruth. 2011. Safety and preliminary evidence of efficacy in a phase I clinical trial of autologous tolerizing dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70: 169.
63. Benham, H., H. J. Nel, S. C. Law, A. M. Mehdi, S. Street, N. Ramnoruth, H. Pahau, B. T. Lee, J. Ng, G. B. ME, C. Hyde, L. A. Trouw, N. L. Dudek, A. W. Purcell, B. J. O’Sullivan, J. E. Connolly, S. K. Paul, K. A. Le Cao, and R. Thomas. 2015. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci. Transl. Med. 7: 290ra87.
64. Buckland, J. 2015. Rheumatoid arthritis: First-in-human phase I trial of DC immunotherapy for early RA. Nat. Rev. Rheumatol. 11: 443.
65. Lim, D. S., M. S. Kang, J. A. Jeong, and Y. S. Bae. 2009. Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur. J. Immunol. 39: 1334-1343.
66. Martin, E., C. Capini, E. Duggan, V. P. Lutzky, P. Stumbles, A. R. Pettit, B. O’Sullivan, and R. Thomas. 2007. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum. 56: 2255-2266.
67. Stoop, J. N., R. A. Harry, D. A. von, J. D. Isaacs, J. H. Robinson, and C. M. Hilkens. 2010. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum. 62: 3656-3665.
68. Nielen, M. M., S. D. van, H. W. Reesink, R. J. van de Stadt, van der Horst-Bruinsma IE, M. H. de Koning, M. R. Habibuw, J. P. Vandenbroucke, and B. A. Dijkmans. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50: 380-386.
69. Isaacs, J. D. 2010. The changing face of rheumatoid arthritis: sustained remission for all? Nat. Rev. Immunol. 10: 605-611.